TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02574728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
Study: NCT04073199

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long Lever Group
Description: the physiotherapist wears the limb passively towards flexion, external rotation and abduction until the physiotherapist has perception of stretch of the tissues (sensation terminal elastic firm according to the concept of Orthopaedic Manual Therapy for the soft tissue treatment) The patient's own weight stabilizes the proximal segment, in case that the scapula is not stable, the physiotherapist fixes with his free hand the scapula.~The technique will be performed two days a week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short Lever Group
Description: It consists of a stretch made by the physiotherapist, with the patient in supine position, with the extremity to be treated in a submaximal position of flexion and external rotation (fixed by the arm and body of the physiotherapist) and realizing the stretch a through the scapula in the medial and caudal dorsal direction.~The technique will be performed two days per week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)
Study: NCT03084289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA ME-TRAP
Description: The candidate vaccine applicable to the clinical trial is the Modified Vaccinia virus Ankara expressing Multiple epitopes and thrombospondin related adhesion protein.
Study: NCT02308319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: 300mg q.d. per oral

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir disoproxil fumarate
Description: 300mg q.d. per oral
Study: NCT02660970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure
Description: Children will have to wear a 'seasickness-band', which has the effect of acupressure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-band
Description: Children will have to wear a 'placebo-wristband'

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iberogast
Description: Children will have to take Iberogast drops

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-drops
Description: Children will have to take placebo-drops
Study: NCT02954211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.~For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
Study: NCT03698084

Intervention type: PROCEDURE
Intervention: venepuncture
Description: sample collection for analysis

Intervention type: PROCEDURE
Intervention: nasopharyngeal swab
Description: sample collection for analysis
Study: NCT00052364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01338675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Study: NCT02350244

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computer program
Description: Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
Study: NCT02350244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer program
Description: Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
Study: NCT00806689

Intervention type: PROCEDURE
Intervention: Cardiac rhythm monitor implantation
Description: post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy

Intervention type: DEVICE
Intervention: Reveal® XT 9525
Description: During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
Study: NCT00425334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemospan (MP4OX)
Description: 250 mL or 500 mL Hemospan (MP4OX)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: 250 mL or 500 mL Ringer's lactate USP
Study: NCT02138396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray (FSS)
Description: A single dose of fentanyl, 400 mcg per sublingual spray
Study: NCT04209205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 6 mg/kg i.v.
Description: AIN457 6 mg/kg delivered by i.v. infusion
Study: NCT02138396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray (FSS)
Description: A single dose of fentanyl, 400 mcg per sublingual spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate Injection (FCI)
Description: A single dose of fentanyl citrate, 100 mcg per intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate Injection (FCI)
Description: A single dose of fentanyl citrate, 100 mcg per intramuscular injection
Study: NCT04209205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AIN457 i.v. infusion
Study: NCT02138396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
Study: NCT01017341

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: PSU hip protector
Description: hip protetor
Study: NCT04350905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mosquito Feeding
Description: Mosquito feedings will be conducted with Aedes aegypti colonies raised at the CNM (National Malaria Center) Malaria and Vector Research Laboratory (MVRL), an established state of the art insectaries for mosquitoes was built in 2014 to ACL2 (arthropodcontainment level 2)-level specifications.
Study: NCT03700736

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Moms
Description: The 6-month intervention will include dietary and exercise counseling and tips to help participants meet their healthy lifestyle goals. Participants will receive personalized calorie and physical activity goals to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Counselors will encourage and support participants to make a plan for incorporating regular physical activity into their lives in a way (i.e., duration per session, frequency per week) that works for that individual woman. We will encourage participants to track their diet and exercise daily. We will encourage participants to use My Fitness Pal to track their diet and activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Moms
Description: The 6-month intervention will include dietary and exercise counseling and tips to help participants meet their healthy lifestyle goals. Participants will receive personalized calorie and physical activity goals to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Counselors will encourage and support participants to make a plan for incorporating regular physical activity into their lives in a way (i.e., duration per session, frequency per week) that works for that individual woman. We will encourage participants to track their diet and exercise daily. We will encourage participants to use My Fitness Pal to track their diet and activity.
Study: NCT01965418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fufang Biejia Ruangan Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00505102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: cyclosporine dose reduced of 50% after introduction of everolimus
Study: NCT02565615

Intervention type: OTHER
Intervention: No intervention
Description: Because this is a non-interventional study, there is no intervention here.
Study: NCT00861679

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transplantation with Stem Cells from Umbilical Cord
Description: According to results from published experiences in children following suggestions are given:~1. Number of Cells:~   * Number of nucleated cells infused exceed 2,5x10\*7/kg recipient BW or~  * Number of nucleated cells collected exceed 3x10\*7/kg BW~  * Number of CD34+ cells infused exceed 2x10\*5/kg Recipient BW~2. GVHD-prophylaxis:~   • MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)~   • UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.~3. HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group MD. Less than 6/6 HLA matches allocate the patient to the MMD group.~4. If many choices available ABO- major incompatibility should be avoided.
Study: NCT02741219

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Control Group receives normal saline bolus after delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dex Group receives dexmedetomidine bolus 0.5mcg/kg after delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: sufentanil PCA after surgery
Study: NCT00956761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza Vaccine (MF59C.1)
Description: 1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
Study: NCT00989508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
Study: NCT02741219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil and dexmedetomidine
Description: sufentanil combined with dexmedetomidine PCA after surgery
Study: NCT00959530

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lingualized occlusion
Description: occlusal surface arranged by lingualized occlusion

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Full Bilaterally Balanced Articulation
Description: occlusal surface arranged by Full Bilaterally Balanced Articulation
Study: NCT02790463

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-Led Intervention
Description: Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
Study: NCT02873364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (High dose)
Description: Daily 4000 unites vitamin D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Low dose)
Description: Daily 600 unites vitamin D
Study: NCT01852929

Intervention type: OTHER
Group type: OTHER
Intervention: Subject using usual positive airway pressure therapy while sleeping for one night
Description: Participants use their usual positive airway pressure therapy while sleeping overnight

Intervention type: OTHER
Group type: OTHER
Intervention: Subject using usual positive airway pressure therapy while sleeping for one night
Description: Participants use their usual positive airway pressure therapy while sleeping overnight
Study: NCT02832596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintained blood pressure
Description: Norepinephrine therapy to maintain preanesthesia blood pressure
Study: NCT02155348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral cataract surgery with implantation of multifocal IOLs
Description: Lentis LS-313, multifocal, target refraction of the distance-dominant eye: 0.00D, target refraction of the other eye: -0.50D

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral cataract surgery with monovision
Description: Lentis L-313, monofocal, target refraction of the distance-dominant eye: 0.00D to -0.25D, target refraction of the other eye: -1.50D

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lentis LS-313

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lentis LS-313
Study: NCT03865511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAGRISSO® 80mg (Osimertinib)
Description: Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Tumor biopsies
Description: Tumor biopsies performed at baseline and clinical progression will be processed (fixed) on site, and sent to Nantes University Hospital for analysis.~The following analysis will be performed:~1. Analyses performed on a regular basis, in order to allow subsequent inclusion in other clinical trials :~   * C797S testing (digital PCR)~  * MET amplification (dPCR/FISH)~  * Histological examination of the tissue sample (to identify small cell transformation)~  * Expression of proteins by immunohistochemistry: PD-L1 (Ventana SP263 antibody); CD73 ; CD4; CD8.~2. At the end of inclusions, deep sequencing analysis to identify acquired mutations and copy number variations (amplifications).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Description: ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial.~These samples will be sent at room temperature by courier to the central laboratory (Nantes University Hospital). There they will be centrifuged, and plasma will be frozen (-80°C).~Analyses :~* Detection of the EGFR activating mutation in plasma at baseline By dPCR (characterization of patients enrolled)~* Detection of the EGFR activating mutation at d7 and m1 by dPCR (early detection of response to osimertinib)~* Analysis of the plasma samples collected at clinical progression in order to identify acquired mechanisms of resistance by NGS (and comparison with analysis of the biopsies).~* Kinetics studies of the alterations
Study: NCT01392378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFANRIX hexa
Description: INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
Study: NCT00989508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo marked PEXSIG
Description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
Study: NCT02826616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
Study: NCT02468232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: The target dose during the study was enalapril 10 mg bid given orally. Enalapril was provided as 2.5 mg, 5 mg, and 10 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to LCZ696
Description: LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Enalapril
Description: Enalapril Placebo 2.5 mg, 5 mg and 10 mg tablets
Study: NCT04497493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)-active
Description: Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type，participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)-sham
Description: Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min 5 days per week, for 4 weeks
Study: NCT02621437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathy sessions
Description: - Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone questionnaires
Description: Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~* pain questionnaire with digital scale,~* quality of life survey: SF-12~* HAD (Hospital and Anxiety Depression) questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: phone questionnaires
Description: Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~* pain questionnaire with digital scale,~* quality of life survey: SF-12~* HAD (Hospital and Anxiety Depression) questionnaire
Study: NCT03363178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3107
Description: BCG Vaccine, 0.1mL
Study: NCT02020590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLOB® implantation
Description: Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
Study: NCT02453893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Study: NCT01986283

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsule
Description: Taken once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00345439
Description: 40 mg capsule swallowed whole, taken once
Study: NCT02453893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study: NCT05345548

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cold Pressor test
Description: Cold Pressor test will be done for 3 minute duration maximum